Veranova has initiated a “significant” expansion of its ADC and highly potent compound development and manufacturing capabilities at Devens, Massachusetts, at a cost of about $30 million. The company said that this will address growing demand for strong US-based capacity for ADCs and other potent small molecules.

Following a review over the past few months of its of its manufacturing capacity relative to customer needs and market trends across its product portfolio, Veranova’s Macfarlan Smith subsidiary has announced a proposal to close its facility at Newbie, near Annan in Scotland. It will now conduct statutory consultation requirements under UK law.

CEO Niek Stapel said: “Every effort has been made to avoid proposing the closure of the plant. This was a difficult decision to make which in no way reflects the performance or commitment of our colleagues at Annan.”